For the millions who live with inflammatory bowel disease, the heart has long been an unexpected casualty — damaged not by any direct assault, but by a slow, invisible conversation between disrupted gut bacteria and wandering immune cells. Researchers at Georgia State University have now traced that conversation to its molecular source, revealing how a compromised intestine reshapes its microbial community, releases bacterial signals into the bloodstream, and ultimately drives immune cells to accumulate in the heart. The discovery places the gut and the heart in a new kind of relationship — no
Gut Inflammation Linked to Heart Disease Through Microbiota Changes, Study Shows
Bacterial signals can reprogram immune cells to migrate into the heart
Mark
So the study shows that gut bacteria changes cause heart problems in IBD patients. But how certain are we that this is what actually happens in people, not just in mice?
Mimi
That's the right question. The mouse work is solid—they transferred microbiota and saw the effect reproduce. But you're right that mice aren't humans. The researchers are showing us the mechanism, the pathway. Whether it operates identically in people requires human studies, which take years.
Luke
And we should note: they demonstrated this in a chronic colitis model. IBD includes ulcerative colitis and Crohn's disease, which have different presentations. The findings may not apply equally to all IBD patients.
Mark
What about the LPS and GBP1 part? Is that the whole story, or are there other molecules involved?
Mimi
They identified LPS and GBP1 as key players, but the immune system is complex. There are likely other pathways they haven't mapped yet. This is one thread they've pulled and followed carefully.
Luke
Right. They showed GBP1 is increased during colitis and that it promotes immune cell recruitment to the heart. But "increased" is relative—we don't know if blocking it entirely would be safe or effective in humans. That's future work.
Mark
The exosome part is interesting—GBP1 traveling in these tiny packages and being taken up by heart cells. Is that a new discovery?
Mimi
It's a new observation in this context. Exosomes as signaling vehicles are well-established, but showing that GBP1-laden exosomes directly affect heart cell enlargement adds a layer to how we understand the gut-heart connection.
Luke
Though again, this is in mice. We don't yet know if exosomal GBP1 is a major driver of cardiac dysfunction in humans or a minor contributor.
Mark
What's the therapeutic angle here? If someone has IBD and is worried about their heart, what does this research actually mean for them right now?
Mimi
Right now, it means researchers have a target to work toward. It doesn't change treatment today. But it suggests that restoring gut microbiota balance—through diet, probiotics, or other interventions—might protect the heart. And it opens the possibility of GBP1-blocking drugs.
Luke
And we should be honest: we don't yet have evidence that modulating GBP1 in humans is safe or effective. This is foundational science pointing toward future therapies, not a therapy itself.
Le Pouls
- IBD patients develop heart disease at rates that have long alarmed clinicians, yet the biological chain of events connecting inflamed intestines to cardiac damage has remained stubbornly invisible — until now.
- Georgia State researchers proved causation rather than correlation by transferring gut microbiota from colitis-afflicted mice to healthy ones, watching the healthy mice develop the same cardiac abnormalities without any intestinal disease of their own.
- The culprit molecule is bacterial lipopolysaccharide, which leaks through a damaged intestinal lining into the bloodstream and triggers immune cells to produce a protein called GBP1 — effectively reprogramming them to migrate toward and accumulate in heart tissue.
- GBP1 also travels inside exosomes, tiny cellular packages absorbed by heart cells, where the protein drives abnormal tissue enlargement known as cardiac hypertrophy, impairing the heart's ability to function.
- Because many pathogens strongly activate GBP family proteins during infection, the findings may extend far beyond IBD — suggesting that cardiac injury following severe illness could operate through this same pathway.
- The research points toward two concrete intervention points — restoring microbial balance in the gut and blocking GBP1 activation — offering a potential shield for IBD patients and, more broadly, anyone whose immune system is pushed into overdrive.
For the millions who live with inflammatory bowel disease, the heart has long been an unexpected casualty — damaged not by any direct assault, but by a slow, invisible conversation between disrupted gut bacteria and wandering immune cells. Researchers at Georgia State University have now traced that conversation to its molecular source, revealing how a compromised intestine reshapes its microbial community, releases bacterial signals into the bloodstream, and ultimately drives immune cells to accumulate in the heart. The discovery places the gut and the heart in a new kind of relationship — not merely neighbors in the body, but participants in a shared biological fate.
People with inflammatory bowel disease have long been known to suffer cardiovascular complications at unusually high rates, yet the mechanism connecting an inflamed intestine to a struggling heart has remained elusive. A research team at Georgia State University's Institute for Biomedical Sciences has now mapped that pathway, and the answer lies in the microscopic community of organisms living in the gut.
Published in Circulation Research, the study demonstrated that chronic colon inflammation reshapes the gut's microbial community in ways that directly damage heart function. The proof came through a transfer experiment: when researchers moved gut microbiota from colitis-afflicted mice into healthy ones, the healthy mice developed the same cardiac abnormalities — establishing that the microbial changes were not merely a byproduct of intestinal disease, but an active driver of heart damage.
The molecular chain begins with lipopolysaccharide, or LPS, a bacterial molecule that leaks into the bloodstream when the intestinal lining is compromised. Circulating LPS triggers immune cells to produce a protein called GBP1, which signals those cells to migrate toward the heart and accumulate there, contributing to cardiac hypertrophy — an abnormal enlargement that impairs function. GBP1 also travels inside exosomes, tiny cellular packages that heart cells absorb, allowing the protein to drive enlargement from within.
Lead researcher Jun Zou described the process as a molecular conversation between the intestine and the heart, conducted through immune cells and bacterial byproducts. Co-senior author Ye Ding noted that many pathogens strongly activate GBP family proteins during infection, suggesting that cardiac injury following severe illness may operate through a similar mechanism — broadening the therapeutic implications well beyond IBD.
For the millions living with inflammatory bowel disease, the findings offer something concrete: if the gut-to-heart pathway runs through microbial imbalance and GBP1 signaling, then restoring that balance or blocking GBP1 activation could interrupt the chain of events before it reaches the heart.
People with inflammatory bowel disease face a puzzle that medicine has not fully solved: their digestive troubles seem to reach the heart. They develop cardiovascular complications at higher rates than the general population, but the mechanism—the actual chain of events connecting inflamed intestines to a struggling heart—has remained opaque. A team at Georgia State University's Institute for Biomedical Sciences has now traced that pathway, and the answer involves microscopic passengers living in the gut.
The researchers published their findings in Circulation Research, demonstrating that chronic colon inflammation reshapes the community of bacteria and other microorganisms in the intestine, and that this reshaping directly damages heart function. They showed this by transferring gut microbiota from mice with colitis to healthy mice. The healthy mice, receiving only the altered microbial community, developed the same cardiac abnormalities as the sick mice. This transfer experiment proved causation: the microbial changes were not merely a side effect of intestinal disease but an active driver of heart damage.
The mechanism turns on a bacterial molecule called lipopolysaccharide, or LPS. When the intestinal lining becomes inflamed and compromised, LPS—produced by certain gut bacteria—leaks into the bloodstream. Once circulating, LPS triggers immune cells to produce a protein called GBP1. This protein then signals those immune cells to migrate toward the heart, where they accumulate and contribute to cardiac hypertrophy, an abnormal enlargement of heart tissue that impairs function. The researchers also discovered that GBP1 travels in exosomes, tiny cellular packages that circulate through the body. When heart cells take up these GBP1-laden exosomes, the protein can drive those heart cells to enlarge as well.
Jun Zou, an assistant professor leading the work, explained the significance plainly: bacterial signals from the gut can reprogram immune cells in ways that promote their movement into the heart, where they fuel abnormal enlargement and dysfunction. The study essentially mapped a molecular conversation between the intestine and the heart, one conducted through immune cells and bacterial byproducts.
The implications extend beyond inflammatory bowel disease. Ye Ding, a co-senior author, noted that many pathogens strongly induce GBP family proteins during infection. While GBP1 normally serves an antimicrobial purpose—helping the body fight off invaders—excessive or dysregulated activation of this protein may inadvertently damage the heart. This suggests that cardiac injury following severe infections might operate through a similar pathway, opening a broader therapeutic window. If researchers can learn to modulate GBP1 activity, they might protect the heart not only in IBD patients but in anyone whose immune system has been pushed into overdrive by infection or chronic inflammation.
The work was supported by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. The findings point toward a potential intervention: if the gut-to-heart pathway runs through microbial dysbiosis and GBP1 signaling, then restoring microbial balance or blocking GBP1 activation might reduce cardiovascular risk in vulnerable populations. For the millions living with inflammatory bowel disease, this represents a concrete target where treatment might interrupt the chain of events that leads from a inflamed intestine to a failing heart.
Citations marquantes
Bacterial signals from the gut can alter immune cells in ways that promote their movement into the heart, where they can contribute to abnormal heart enlargement and impaired function.— Jun Zou, assistant professor, Institute for Biomedical Sciences at Georgia State University
Many pathogens strongly induce GBP family proteins, and excessive or dysregulated GBP1 activation may inadvertently contribute to cardiac dysfunction beyond IBD.— Ye Ding, co-senior author and research associate professor, Institute for Biomedical Sciences at Georgia State University
Envie de l'histoire complète ?
Lire l'original sur EurekAlert! Science News Releases ↗
Science & Space